Joana Ribeiro

University of North Carolina at Chapel Hill — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

17h-index1.4kcitations76works5.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Breast Cancer Treatment Studies(17), Cancer Immunotherapy and Biomarkers(16), Advanced Breast Cancer Therapies(13), HER2/EGFR in Cancer Research(12), Cancer Treatment and Pharmacology(10)

Publications71 total

Immune checkpoint inhibitors for patients with metastatic triple-negative inflammatory breast cancer (INCORPORATE): An international cohort study
UNC Libraries·2025Open Access
PROMENADE: pembrolizumab for early ER-low/HER2-negative breast cancer, real-world French cohort
ESMO Open·2025· 1 citedOpen Access
Physiotherapeutic protocol for the studies of the effects of photobiomodulation on breast cancer
Manual Therapy Posturology & Rehabilitation Journal·2025Open Access
Abstract B054: Correspondence between circulating tumor DNA (ctDNA)-based <i>ERBB2</i> amplification and HER2 expression by IHC/ISH across solid tumors: Molecular landscape and diagnostic implications
Molecular Cancer Therapeutics·2025
Erratum: Identifying Patients With Low Relapse Rate Despite High-Risk Estrogen Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Early Breast Cancer: Development and Validation of a Clinicopathologic Assay
Journal of Clinical Oncology·2025
AVALIAÇÃO DA CONTAGEM SANGUÍNEA DE CÉLULAS NATURAL KILLER (NK) COMO FATOR PREDISPONENTE DE MUCOSITE E DE IMPACTO NO DESFECHO CLÍNICO DURANTE A QUIMIOTERAPIA DE INDUÇÃO EM PACIENTES COM LEUCEMIA AGUDA
Hematology Transfusion and Cell Therapy·2025Open Access
308P Clinicopathologic features, patterns of care, and survival outcomes with endocrine therapy omission of ER-low breast cancer: CANTO cohort analysis
Annals of Oncology·2025
296O Risk of recurrence (ROR) after neoadjuvant ribociclib plus ET in clinically high-risk ER+/HER2− BC: Preliminary analysis of the SOLTI-RIBOLARIS trial
Annals of Oncology·2025· 2 cited
Identifying Patients With Low Relapse Rate Despite High-Risk Estrogen Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Early Breast Cancer: Development and Validation of a Clinicopathologic Assay
Journal of Clinical Oncology·2025· 4 citedOpen Access
Prediction of Breast Cancer Response to Neoadjuvant Therapy with Machine Learning: A Clinical, MRI-Qualitative, and Radiomics Approach
Life·2025Open Access
Abstract P1-02-13: Longitudinal analysis of cancer-related cognitive impairment in patients with luminal-like breast cancer undergoing chemotherapy and/or endocrine therapy - the Champalimaud-Helsinki study
Clinical Cancer Research·2025
Abstract P5-11-21: Pembrolizumab impact on surgery and radiation therapy in non-metastatic triple negative breast cancer treatment
Clinical Cancer Research·2025
Abstract P2-10-28: COMPASS-TNBC - A phase Ib/II, open-label, modular, dose-finding and dose-expansion study to explore safety and anti-tumor activity of novel therapeutics in patients with early relapsed mTNBC. Module 1: Dato-DXd &amp; Module 2: Dato-DXd + durvalumab
Clinical Cancer Research·2025
Short-term pre-operative durvalumab (MEDI 4736) in early small triple-negative breast cancer patients (POP-Durva).
Journal of Clinical Oncology·2025
Prognostic value of systemic inflammation in early-stage breast cancer in the CANTO cohort (SIM-CANTO).
Journal of Clinical Oncology·2025
IDENTIFICAÇÃO DE INCIDENTES E ESTRATÉGIAS RELACIONADOS A SEGURANÇA DO PACIENTE NA ATENÇÃO PRIMÁRIA À SAÚDE
Aracê.·2025Open Access
Unveiling the Potential of Cyclin-Dependent Kinases 4 and 6 Inhibitors Beyond Progression in Hormone Receptor Positive/Human Epidermal Growth Factor Negative Advanced Breast Cancer – A Clinical Review
Current Treatment Options in Oncology·2024· 3 citedOpen Access
Immune checkpoint inhibitors for patients with metastatic triple-negative inflammatory breast cancer (INCORPORATE): An international cohort study
European Journal of Cancer·2024· 5 cited
Zebrafish Avatar-test predicts patient’s tumor response to chemotherapy in breast cancer: a co-clinical study towards personalized medicine
2024· 1 citedOpen Access
Long-term behavioral symptom clusters among survivors of early-stage breast cancer: Development and validation of a predictive model
JNCI Journal of the National Cancer Institute·2024· 9 cited
page 1 of 4Next →

Frequent Co-authors

Inês Vaz-Luís(12), Fátima Cardoso(10), Fabrice André(10), Barbara Pistilli(9), Arlindo R. Ferreira(7), Antonio Di Meglio(6), Maria Alice Franzoi(6), Luís Costa(6), Berta Sousa(5), Maria João Cardoso(5), Davide Soldato(4), Martina Pagliuca(4), Otto Metzger(4), Olivier Trédan(4), Stefan Michiels(4), Elie Rassy(4), Quentin Blampey(4), Nadège Bercovici(4), Isabelle Pic(4), João Fernandes(4)